The Grampian region early anistreplase trial (GREAT) assessed the feasibility, safety, and efficacy of prehospital thrombolysis given by general practitioners. This treatment was shown to be feasible and safe in their hands, and at one year a halving of mortality was reported ($p = 0.007$). Seven other small randomised trials comparing prehospital with hospital thrombolysis have been published, and although none showed significant benefit at one month, meta-analysis has confirmed the value of prehospital thrombolysis.

Standard 6 of the National Service Framework for coronary heart disease requires that thrombolysis should be given within 60 minutes of calling for professional help. Since GREAT has been influential in informing policy decisions and formulating this target, the 10 year results are presented in this paper.

**PATIENTS AND METHODS**

The trial and the results at three months were fully described in 1992. Twenty nine rural practices in Grampian participated, and these were located 26–100 km (mean 58 km) by road from Aberdeen where all patients were admitted to hospital. Three hundred and eleven patients with suspected acute myocardial infarction seen within four hours of symptom onset and without contraindications to thrombolytic treatment were recruited between December 1988 and 31 December 1991: 163 patients were randomly allocated to the "prehospital" group and received anistreplase 30 units intravenously from their general practitioners, followed by placebo after admission to hospital; 148 patients in the "hospital" group received placebo prehospital followed by anistreplase in hospital. The median time intervals from onset of symptoms to administration of anistreplase were 1.75 and 4 hours in prehospital and hospital groups, respectively.

General practitioners recorded an ECG but were not required to interpret it for trial entry; 180 patients had ST elevation or bundle branch block (BBB) on either the prehospital recording or the first recording in hospital. All patients were flagged with the Scottish Registry Office and their deaths notified to us. Follow up data has been censored at the 10th anniversary of trial entry.

**RESULTS**

In 10 years there were 142 deaths, 73/163 in the prehospital group, and 69/148 in the hospital group. Survival curves for prehospital and hospital groups are shown in fig 1. The curves diverge for the first two years, and then converge.

Improved survival with prehospital thrombolysis was confined to those with ST elevation or BBB, and fig 2 compares survival curves for prehospital and hospital groups in the 180 patients with these abnormalities.

**DISCUSSION**

All discussion of GREAT must be prefaced with the caveat that the trial was small, the confidence intervals large, and the conclusions necessarily tentative.

Ten year follow up of GREAT has reaffirmed the value of prehospital thrombolysis that was apparent when the first results of the trial were published in 1992. In spite of the late convergence of the survival curves, patients in the prehospital group enjoyed an appreciable survival advantage compared with those in the hospital group. The area between the survival curves in fig 1 is equivalent to 0.9 (95% confidence interval (CI) –0.1 to 1.9; 7.4 v 6.5) years, and represents the additional survival enjoyed on average by each of the patients in the prehospital group compared with those in the hospital group during 10 years' follow up.

Entry into GREAT did not require electrocardiographic confirmation of the diagnosis, although an ECG was recorded. Nowadays, the presence of ST elevation or bundle branch block on the presenting ECG is generally considered a prerequisite for thrombolytic treatment. Our results endorse this policy, showing that the benefits of prehospital thrombolysis
are confined to those with these ECG abnormalities. In the subset of GREAT patients who met the current ECG criteria for thrombolysis, the average survival advantage following prehospital thrombolysis was 1.6 (95% CI 0.5 to 2.6; 7.4 vs 5.9) years, equivalent to a 16% average difference in mortality maintained over 10 years. It is possible that the extended benefit seen in the first two years would have been maintained and enhanced if prehospital thrombolysis had been complemented with an aggressive surgical reperfusion strategy.  

Prehospital thrombolysis continues to be practised in Grampian, and there has been some expansion of its use in rural Scotland. In England and Wales only a handful of general practitioners are known to be using this treatment, and in pilot projects in two ambulance trusts only a few patients have been treated by paramedics. Implementation of prehospital thrombolysis is 10 years overdue.

ACKNOWLEDGEMENTS

The names of the general practitioners who participated so magnanimously are given in reference 1. The trial was supported by Smith-Kline Beecham. Long term follow up was funded by a grant from the Health Department.

REFERENCES


IMAGES IN CARDIOLOGY

Management of complex, two chamber false aneurysm by thrombin injections

False aneurysms develop at the puncture site in up to 6% of percutaneous cardiovascular procedures. Previous management of false aneurysms consisted of surgical repair or compression therapy. Drawbacks of surgery are its invasiveness, compression therapy pain, and prolonged compression bandages. An alternative to both is selective injection of thrombin into the false aneurysm. However, its effectiveness in complex, double chamber aneurysms in patients treated with enoxaparin, aspirin and clopidogrel, and abciximab is not clear as yet.

After an acute invasive procedure using a 6 French sheath in a 79 year old man with acute myocardial infarction, a complex two chamber false aneurysm occurred. The patient was not suitable for compression therapy because of intense pain, despite local lidocaine injections and systemic morphine (15 mg). The surgeons refused to operate on the patient because of systemic anticoagulation (enoxaparin subcutaneously, 1.0 ml twice per day) and treatment with aspirin (500 mg initial dose, followed by 100 mg/day), clopidogrel (300 mg initial dose, followed by 75 mg/day) and weight adjusted abciximab.

To induce clot formation, “chamber I” was punctured percutaneously under ultrasound guidance with a 20 gauge needle. Brief aspiration and re-injection of blood confirmed the correct position of the needle. After injection of 550 U of diluted thrombin solution (GenTrac, Middleton, Wisconsin, USA) thromboses of both chambers occurred. The patient received a cool pack for two hours. No complications occurred until hospital discharge.

Therefore, thrombin injections are effective for management of false aneurysms, even in patients with a complex anatomy and treatment with systemic anticoagulation and high dose anti-aggregation therapy.

G Görge
T Kunz

www.heartjnl.com

GREAT: 10 year survival of patients with suspected acute myocardial infarction in a randomised comparison of prehospital and hospital thrombolysis

J Rawles

*Heart* 2003 89: 563-564

doi: 10.1136/heart.89.5.563

Updated information and services can be found at: [http://heart.bmj.com/content/89/5/563](http://heart.bmj.com/content/89/5/563)

These include:

**References**

This article cites 5 articles, 1 of which you can access for free at: [http://heart.bmj.com/content/89/5/563#BIBL](http://heart.bmj.com/content/89/5/563#BIBL)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Clinical diagnostic tests (4779)
- Acute coronary syndromes (2742)
- Epidemiology (3767)
- Pacing and electrophysiology (266)

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)